ArticleScience (New York, N.Y.)2023
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors.
Article in Science (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07022366 (Investigating the Neuropsychological Effects of 5-HT2a Antagonism), which is not on this map. Cited by 258 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigating the Neuropsychological Effects of 5-HT2a Antagonism
Who cites it
258 citing papers in PubMed, 9 syntheses or guidelines pooled it, 420 citations in OpenAlex.
- Efficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis.Journal of psychopharmacology (Oxford, England) · 2026Pooled it
- The Use of Psychedelics in the Treatment of Adult ADHD: A Systematic and Mechanistic Review.International journal of molecular sciences · 2026Pooled it
- Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence.Acta neuropsychiatrica · 2025Pooled it
- Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.Molecular psychiatry · 2025Pooled it
- Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis.Molecular psychiatry · 2025Pooled it
- Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis.Clinical pharmacokinetics · 2025Pooled it
- Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis.Clinical pharmacokinetics · 2025Pooled it
- Exploring the bidirectional relationship between depressive disorder and dyslipidemia: a systematic review and meta-analysis.Frontiers in psychiatry · 2025Pooled it
- Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.BMJ (Clinical research ed.) · 2024Pooled it
- Neuroplastic white matter changes in patients with major depression following lysergic acid diethylamide treatment.Cell reports. Medicine · 2026Trial
- Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h N,N-Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Trial.Clinical and translational science · 2025Trial
- Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial.The international journal of neuropsychopharmacology · 2024Trial
- Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024Trial
- Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Sustained antidepressant-like effects of psychedelics through 5-HTNature neuroscience · 2026Article
- Serotonin 1B receptors expressed on forebrain excitatory neurons mediate the post-acute anxiolytic response to psilocybin in mice.Psychopharmacology · 2026Article
- 5-HTNature neuroscience · 2026Article
- Psychedelics and disorders of consciousness: a new frontier in neurotherapeutics.Molecular psychiatry · 2026Review
- Deconstruction of lysergic acid diethylamide.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults.Pharmaceuticals (Basel, Switzerland) · 2026Article
198 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
Decreased dendritic spine density in the cortex is a hallmark of several neuropsychiatric diseases, and the ability to promote cortical neuron growth has been hypothesized to underlie the rapid and sustained therapeutic effects of psychedelics. Activation of 5-hydroxytryptamine (serotonin) 2A receptors (5-HT2ARs) is essential for psychedelic-induced cortical plasticity, but it is currently unclear why some 5-HT2AR agonists promote neuroplasticity, whereas others do not. We used molecular and genetic tools to demonstrate that intracellular 5-HT2ARs mediate the plasticity-promoting properties of psychedelics; these results explain why serotonin does not engage similar plasticity mechanisms. This work emphasizes the role of location bias in 5-HT2AR signaling, identifies intracellular 5-HT2ARs as a therapeutic target, and raises the intriguing possibility that serotonin might not be the endogenous ligand for intracellular 5-HT2ARs in the cortex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.